Orgenesis Profile

5.60
USD 0.02  0.36%
25%
71%

Sale by Universite Libre De Bruxelles of 204396 shares of Orgenesis

Orgenesis Inc insider trading alert for sale of common stock by Universite Libre De Bruxelles, the corporate stakeholder, on March 22, 2018. This event was filed by Orgenesis Inc with SEC on 2018-03-22. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Orgenesis Summary

Orgenesis (ORGS) is traded on BATS Exchange in USA. It is located in MARYLAND U.S.A and employs 103 people. Orgenesis is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 102.82 M. Orgenesis conducts business under Healthcare sector and is part of Biotechnology industry. This company has 14.99 M outstanding shares of which 70.42 K shares are now shorted by private and institutional investors with about 2.57 trading days to cover. ORGENESIS INC currently holds about 4.5 M in cash with (8.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.31.
Check Orgenesis Probability Of Bankruptcy

Ownership Allocation (%)

Orgenesis Target Price Odds Analysis

Odds Below 5.6HorizonTargetOdds Above 5.6
53.75%30 days 5.60 46.17%
Based on normal probability distribution, the odds of Orgenesis to move above current price in 30 days from now is about 46.17% (This Orgenesis probability density function shows the probability of Orgenesis Stock to fall within a particular range of prices over 30 days) .

Orgenesis Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares144.8 K1.3 M
Blackrock IncCommon Shares19.2 K166 K
View Orgenesis Diagnostics

Orgenesis Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Orgenesis Key Fundamentals

Orgenesis Against Markets

Orgenesis Current Ratings

Orgenesis 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
1 
Equity ratings for Orgenesis are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 103 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Orgenesis SEC Filings
Orgenesis SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameOrgenesis
CEO of Orgenesis Maryland IncScott CarmerView All
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
LocationMARYLAND U.S.A
Business Address20271 Goldenrod Lane
ExchangeBATS Exchange
CUSIP123290108
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.orgenesis.com
Phone480 659 6404
Related EntityBOUT
CurrencyUSD - US Dollar
Next Fiscal Year EndNovember 30, 2019
Most Recent QuarterMay 31, 2018
Last Fiscal Year EndNovember 30, 2017
Date Short InterestJuly 31, 2018

Orgenesis Directors

Orgenesis Corporate Directors

David Sidransky Director
Yaron Adler Director
Marie Bouillez Director
Additionally take a look at Your Equity Center. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Search macroaxis.com